Get started
Author

Théa Faivre

Observed names: T. Faivre, Thea Faivre
ORCID: 0000-0003-2090-2477
Observed ORCID: 0000-0003-2090-2477
OpenAlex ID: A5087218547
Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection
2022 · Anna Morena D’Alise, Nadia Brasu, et al. · Science Translational Medicine · 70
Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
2023 · Michael J. Overman, Joan Maurel, et al. · Journal of Clinical Oncology · 17
410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI)
2021 · Michael Overman, Marwan Fakih, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).
2022 · Marwan Fakih, Dung T. Le, et al. · Journal of Clinical Oncology · 10
Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.
2012 · Jeffrey R. Infante, Leena Gandhi, et al. · Journal of Clinical Oncology · 9
Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.
2013 · Chris Verslype, Pascal Hammel, et al. · Journal of Clinical Oncology · 5
706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study
2022 · Oliver Bechter, Juan Martin-Liberal, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
1004P Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability
2021 · M.J. Overman, G. Leoni, et al. · Annals of Oncology · 4
A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies
2017 · Amer M. Zeidan, Rachel J. Cook, et al. · Blood · 4
Abstract CT056: Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies
2016 · Andres Forero-Torres, Michael S. Wertheim, et al. · Cancer Research · 2
Baseline characteristics and interim analysis results of TRANSITION: a 2-year observational study evaluating the safety profile of patients with multiple sclerosis who switched from natalizumab to fingolimod
2015 · Helmut Butzkueven, Belinda Weller, et al. · Multiple Sclerosis Journal · 2
Phase 3 study to assess the safety and efficacy of 177 Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).
2026 · David Cade, Sumanta Kumar Pal, et al. · Journal of Clinical Oncology · 1
Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102).
2017 · Morton Coleman, Antonio Salar, et al. · Journal of Clinical Oncology · 1
84 Phase 3 Study to Assess the Safety and Efficacy of 177Lu-girentuximab in Advanced, Relapsed or Recurrent ccRCC (LUTEON; NCT07197580)
2026 · Sumanta Pal, Andrew Scott, et al. · The Oncologist
PDF
Phase 3 Study to Assess the Safety and Efficacy of 177Lu-girentuximab in Advanced, Relapsed or Recurrent ccRCC (LUTEON)
2026 · Aviral Singh, Andrew Scott, et al. · World Journal of Nuclear Medicine
Abstract LB008: Characterization of immune correlates of clinical activity for Nous-209, an off-the-shelf immunotherapy, with pembrolizumab for treatment of tumors characterized by microsatellite instability (MSI)
2022 · Anna Morena D'Alise, Guido Leoni, et al. · Cancer Research
Works count: 16
Citation count: 143
H-index: 5
I10-index: 4
Year
Topic
Type